Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
Want to see ZLDAF full AI Analyst Report?
ZLDAF Stock Chart & Stats
$0.21
-$0.03(-7.39%)
At close: 4:00 PM EST
$0.21
-$0.03(-7.39%)
Day’s Range― - ―
52-Week Range$0.20 - $0.48
Previous CloseN/A
Volume342.00
Average Volume (3M)189.00
Market Cap
$4.32M
Enterprise Value$8.08M
Total Cash (Recent Filing)$5.66K
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume15
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market Cap1.87
Enterprise Value/Revenue12.34K
Enterprise Value/Gross Profit-10.07
Enterprise Value/Ebitda-1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Monetization StrategyZelira targets two durable revenue streams: direct commercialization of proprietary cannabinoid products and B2B licensing/co-development. Over 2–6 months this mix can reduce dependence on a single channel, enable recurring licensing revenue, and let the company scale via partners without proportional capex.
Proprietary Cannabinoid Product FocusA dedicated pipeline and IP focus in cannabinoid formulations creates a specialized niche and potential technical barriers to entry. Durable R&D specialization supports licensing, co-development deals, and product differentiation that underpin medium-term commercial and partnership opportunities.
Early Signs Of Cash-flow ImprovementWhile cash flows remain negative, a modest improvement in free cash flow growth signals initial progress on operational efficiency or monetization. If sustained, this trend can reduce financing needs, extend runway, and support incremental commercialization or partner investments over the coming months.
Bears Say
Severe Revenue CollapseA near-total top-line collapse materially weakens the firm's ability to fund R&D, commercial launches, and partnership commitments. Over 2–6 months, such a decline undermines scale economics, bargaining power with distributors, and the feasibility of sustaining independent commercialization without new revenue sources.
Negative Shareholders' EquityNegative equity signals structural balance-sheet weakness that limits financial flexibility. It constrains access to debt, increases the probability of dilutive equity raises, and can deter partners or licensors. These effects are durable and can materially hinder strategic options over months.
Persistent Negative Margins And Cash FlowsSustained negative margins and cash burn mean the business is not self-funding. Over the medium term this reduces reinvestment capacity, forces reliance on external financing, and raises execution risk for commercialization and R&D programs unless margins or revenue recover meaningfully.
Zelira Therapeutics News
ZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.20 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.32M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 114 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―